TiCARos

TiCARos is a developer of CAR-T cell therapy aimed at treating patients with relapsed and refractory cancer. The company's technology enhances the efficacy of T cells by selectively inhibiting CTLA4 only in cancer-specific T cells, and increases tumor elimination by modifying the CAR structure to allow more CAR-T cells to bind with tumor cells, enabling patients to benefit from new cancer treatment methods.